Evaxion Biotech A/S Stock

Equities

EVAX

US29970R2040

Biotechnology & Medical Research

Delayed Nasdaq 12:15:56 2024-05-03 pm EDT 5-day change 1st Jan Change
3.979 USD +2.28% Intraday chart for Evaxion Biotech A/S -4.82% -41.98%
Sales 2024 * 6.27M Sales 2025 * 18.26M Capitalization 21.05M
Net income 2024 * -11M Net income 2025 * -3M EV / Sales 2024 * 3.36 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.15 x
P/E ratio 2024 *
-2.8 x
P/E ratio 2025 *
-1.97 x
Employees 49
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.4%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
Evaxion Announces Phase 2 Clinical Trial Update CI
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading MT
Certain Warrants of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
Certain American Depositary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
Certain Ordinary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
ADRs End Lower; Meta Data Slides 22% DJ
More news
1 day+0.39%
1 week-4.82%
Current month-4.59%
1 month+10.52%
3 months-6.38%
6 months-65.10%
Current year-41.98%
More quotes
1 week
3.85
Extreme 3.85
4.31
1 month
3.52
Extreme 3.52
4.41
Current year
2.82
Extreme 2.8243
13.61
1 year
2.82
Extreme 2.8243
18.50
3 years
2.82
Extreme 2.8243
250.40
5 years
2.82
Extreme 2.8243
250.40
10 years
2.82
Extreme 2.8243
250.40
More quotes
Managers TitleAgeSince
Founder - 08-08-10
Founder 46 08-08-10
Chief Executive Officer 52 23-08-28
Members of the board TitleAgeSince
Director/Board Member 54 17-12-31
Director/Board Member 66 21-05-24
Chairman 56 17-12-31
More insiders
Date Price Change Volume
24-05-03 3.979 +2.28% 12 217
24-05-02 3.89 -0.51% 7,567
24-05-01 3.91 -6.24% 3,741
24-04-30 4.17 -2.80% 9,644
24-04-29 4.29 +2.63% 16,494

Delayed Quote Nasdaq, May 03, 2024 at 12:15 pm EDT

More quotes
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.89 USD
Average target price
11.75 USD
Spread / Average Target
+202.06%
Consensus